Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Bart Burington"'
Autor:
Gabriela M. Baerlocher, Monika Haubitz, Thomas R. Braschler, Claudio Brunold, Bart Burington, Elisabeth Oppliger Leibundgut, Ning Go
Publikováno v:
Blood Advances, Vol 3, Iss 22, Pp 3724-3728 (2019)
Externí odkaz:
https://doaj.org/article/f63431f1b161493d9cfdaa6db3239b31
Autor:
Elisabeth Oppliger Leibundgut, Monika Haubitz, Bart Burington, Oliver G. Ottmann, Gary Spitzer, Olatoyosi Odenike, Michael A. McDevitt, Alexander Röth, David S. Snyder, Gabriela M. Baerlocher
Publikováno v:
Haematologica, Vol 106, Iss 9 (2020)
In a phase-2 study, the telomerase inhibitor imetelstat induced rapid hematologic responses in all patients with essential thrombocythemia who were refractory or intolerant to prior therapies. Significant molecular responses were achieved within 3-6
Externí odkaz:
https://doaj.org/article/43c8a3ad977a49d995ade2d9c11aaebf
CCR Translation on this Article from Tumor Cell Gene Expression Changes Following Short-term In vivo Exposure to Single Agent Chemotherapeutics are Related to Survival in Multiple Myeloma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8f45880c78a9d76a461af7af0a17b1ec
https://doi.org/10.1158/1078-0432.22439407.v1
https://doi.org/10.1158/1078-0432.22439407.v1
Changes in global gene expression patterns in tumor cells following in vivo therapy may vary by treatment and provide added or synergistic prognostic power over pretherapy gene expression profiles (GEP). This molecular readout of drug-cell interactio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b0dae6f55fb3f338b424f7844650751d
https://doi.org/10.1158/1078-0432.c.6516871.v1
https://doi.org/10.1158/1078-0432.c.6516871.v1
Autor:
Monika Haubitz, David S. Snyder, Michael A. McDevitt, Oliver G. Ottmann, Elisabeth Oppliger Leibundgut, Olatoyosi Odenike, Gabriela M. Baerlocher, Bart Burington, Alexander Röth, Gary Spitzer
Publikováno v:
Haematologica
In a phase-2 study, the telomerase inhibitor imetelstat induced rapid hematologic responses in all patients with essential thrombocythemia who were refractory or intolerant to prior therapies. Significant molecular responses were achieved within 3-6
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::241a48c1a92dbc252eb19f6fbc502162
https://doi.org/10.3324/haematol.2020.252817
https://doi.org/10.3324/haematol.2020.252817
Autor:
Monika Haubitz, Elisabeth Oppliger Leibundgut, Ning Go, Gabriela M. Baerlocher, Claudio Brunold, Thomas R. Braschler, Bart Burington
Key Points Clinically relevant imetelstat concentrations significantly inhibit CFU-MEG formation from MNCs of ET patients and reduce hTERT expression. However, similar concentrations of imetelstat do not inhibit cytokine-induced CFU-MEG from MNCs of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::001bac2c73ba141cbc2125b13e003268
https://europepmc.org/articles/PMC6880912/
https://europepmc.org/articles/PMC6880912/
Autor:
Fotios Koumpouras, Anca D. Askanase, Paul J. Foster, Joshua June, Judith A. James, Arezou Khosroshahi, Joan T. Merrill, Saira Z Sheikh, Wambui Machua, Joel M. Guthridge, Gaurav Rathi, Debra Zack, Mohammad Faisal Khan, Bart Burington
Publikováno v:
Poster Presentations.
Background: XmAb5871 is a humanized anti-CD19 antibody Fc-engineered for increased affinity to FcγRIIb. Co-ligation of CD19 and FcγRIIb inhibits B lineage cells key to SLE pathogenesis. Objectives: This Phase 2 study was designed to minimize backgr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::69b26fd9d69dc48e4ca901607a69c1be
https://doi.org/10.1136/annrheumdis-2019-eular.4234
https://doi.org/10.1136/annrheumdis-2019-eular.4234
Autor:
Tatjana Kolevska, Normand Blais, J. von Pawel, Mark U. Rarick, S. Gadgeel, Alberto Chiappori, David R. Spigel, Joan H. Schiller, Martin Reck, Steven Hager, Bart Burington, Lowell L. Hart, Ekaterina Bassett
Publikováno v:
Annals of Oncology. 26:354-362
Imetelstat, a novel telomerase inhibitor, failed to improve significantly median PFS and OS as maintenance therapy (±bevacizumab) in advanced NSCLC. Telomere length (TL) biomarker results were consistent with the hypothesis that telomerase inhibitio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a76622af4d486d892be15b322f2a1979
https://doi.org/10.1093/annonc/mdu550
https://doi.org/10.1093/annonc/mdu550
Publikováno v:
Baerlocher, Gabriela M.; Burington, Bart; Snyder, David S (2015). Telomerase Inhibitor Imetelstat in Essential Thrombocythemia and Myelofibrosis. New England journal of medicine NEJM, 373(26), p. 2580. Massachusetts Medical Society MMS 10.1056/NEJMc1512663
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77a8645e474911ad55fe10dff1891495
https://doi.org/10.1056/nejmc1512663
https://doi.org/10.1056/nejmc1512663